Rion structures itself as a central "hub" with core technology, then creates separate "spoke" companies for verticals like veterinary or cosmetics. These spokes raise their own targeted capital, allowing Rion to fund platform development without constant dilution at the parent company level and diversifying funding risk.
Rion strategically chose diabetic foot ulcers as its lead indication to de-risk its new therapeutic class. This "outside-in" approach allows the company to build a substantial safety record and gain regulatory and clinical acceptance with a topical product before advancing to more complex systemic applications.
Rion avoids disrupting the medical platelet supply by sourcing near-expiration units from blood banks. This provides an abundant, low-cost raw material. In return, blood banks gain a revenue stream for products that would be discarded, encouraging them to maintain larger inventories for transfusions, creating a win-win.
Rion's research, initially focused on stem cells, revealed their regenerative properties were not intrinsic. Instead, the cells were recycling platelet content from their culture medium, and these recycled components were the true source of the therapeutic effect. This finding prompted a strategic pivot away from stem cells.
Rion found that culturing stem cells in a lab to force division leads to rapid DNA damage, as cells are not designed for this artificial environment. This damage created inconsistent exosome products, making large-scale, uniform manufacturing from stem cells unfeasible and prompting a search for a more stable source.
Unlike many cell therapies, Rion's platelet-derived exosomes are devoid of the self/non-self surface markers that trigger immune rejection. This "immune privilege" is a critical biological advantage, allowing the product to be used as a universal, off-the-shelf therapy for any patient without needing donor matching.